Medindia9h
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...
Novartis Receives Third FDA Approval For Oral Fabhalta® (Iptacopan) - The First And Only Treatment Approved In C3 Glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety1 <li /> Fabhalta is the only or ...
National Bureau of Economic Research13h
Systemic Risk Measures: Taking Stock from 1927 to 2023
We assess the efficacy of systemic risk measures that rely on U.S. financial firms’ stock return co-movements with market- or sector-wide returns under stress from 1927 to 2023. We ascertain stress ...